An automated "sample-to-answer" system could provide Ebola virus disease (EVD) diagnosis more quickly and easily than the current standard test, according to research published this week in PLOS Medicine. In a field evaluation study, Nira Pollock of Boston Children's Hospital and colleagues from Public Health England and Partners In Health found that the Cepheid GeneXpert Ebola assay provided results in near agreement with the standard laboratory test for both whole blood (WB) and cheek swab (buccal swab, BS) samples.
The standard laboratory test used for EVD diagnosis in this field evaluation requires sample inactivation, nucleic acid extraction and reverse transcription polymerase chain reaction (RT-PCR) using the "Trombley assay"; the GeneXpert Ebola assay is an automated RT-PCR system that integrates all the steps, once sample has been inactivated and loaded into a cartridge. Dr. Pollock and colleagues compared results from the two assays in the Public Health England EVD diagnostic laboratory in Port Loko, Sierra Leone, using residual diagnostic specimens remaining after clinical testing. The researchers tested 218 WB samples collected through venipuncture from patients with suspected or confirmed EVD, as well as 71 BS samples collected as part of a national postmortem screening program. After excluding a few samples that gave Xpert results that were reported as "invalid" or "error," 22 out of 22 Trombley-positive WB samples were Xpert-positive (sensitivity of 100%), and 181 out of 189 Trombley-negative WB samples were Xpert-negative (specificity of 95.8%). In 64 BS samples with valid results for both Trombley and Xpert, the sensitivity and specificity of the Xpert assay were both 100%. For blood samples with enough volume for two tests, the researchers also compared sampling blood using a pipette versus a swab and found that 78 of 79 paired results were concordant, suggesting that collection of the same volume of fingerstick blood using a swab (which is potentially easier to do in the field) may also provide accurate results when using the GeneXpert assay.
These findings suggest that the use of the Xpert Ebola assay could facilitate expanded access to Ebola virus testing. However, the authors note that formal testing of fingerstick samples is needed before these samples are used for diagnosis with Xpert, and that evaluation of a larger set of fresh BS samples would also be optimal. The system should also be evaluated in more remote facilities as the need for an uninterrupted power supply, potential refrigeration of reagents, and platform validation/maintenance may prevent its wide deployment. The authors say, "[O]ur data indicate that the Xpert Ebola assay has excellent performance in a field laboratory setting using both WB and BS specimens and thus provides the opportunity for highly accurate, rapid sample-to-answer diagnosis of EVD".
Funding for the study was provided by a gift from the Abundance Foundation. Cepheid provided a platform and test kits for the study but did not provide any monetary support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
I have read the journal's policy and the authors of this manuscript have the following competing interests: MM is a member of the Editorial Board of PLOS Medicine. The authors declare that no further competing interests exist.
Semper AE, Broadhurst MJ, Richards J, Foster GM, Simpson AJH, Logue CH, et al. (2016) Performance of the GeneXpert Ebola Assay for Diagnosis of Ebola Virus Disease in Sierra Leone: A Field Evaluation Study. PLoS Med 13(3): e1001980. doi:10.1371/journal.pmed.1001980
Public Health England, Porton Down, United Kingdom
Partners In Health, Boston, Massachusetts, United States of America
Public Health England Laboratory, Port Loko, Sierra Leone
Mid Essex Hospital Services NHS Trust, Chelmsford, United Kingdom
Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Wellbody Alliance, Freetown, Sierra Leone
Harvard Medical School, Boston, Massachusetts, United States of America
Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts, United States of America
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:
Nira R. Pollock
Associate Medical Director, Infectious Diseases Diagnostics Laboratory
Boston Children's Hospital
300 Longwood Avenue, Bader 761
Boston, MA 02115